Bayesian Capital Management LP acquired a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 16,073 shares of the medical instruments supplier's stock, valued at approximately $3,646,000.
A number of other institutional investors also recently added to or reduced their stakes in BDX. Bank of Jackson Hole Trust bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at about $25,000. Sierra Ocean LLC acquired a new stake in Becton, Dickinson and Company in the fourth quarter valued at approximately $29,000. Picton Mahoney Asset Management grew its holdings in Becton, Dickinson and Company by 61.4% in the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after purchasing an additional 54 shares during the last quarter. Hopwood Financial Services Inc. purchased a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at $39,000. Finally, Versant Capital Management Inc boosted its position in shares of Becton, Dickinson and Company by 54.1% in the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier's stock worth $47,000 after purchasing an additional 73 shares in the last quarter. Institutional investors own 86.97% of the company's stock.
Becton, Dickinson and Company Price Performance
NYSE:BDX opened at $168.61 on Friday. The firm's fifty day moving average is $214.76 and its two-hundred day moving average is $225.60. The firm has a market cap of $48.41 billion, a price-to-earnings ratio of 28.01, a PEG ratio of 1.63 and a beta of 0.35. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. Becton, Dickinson and Company has a one year low of $166.11 and a one year high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. The firm had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. The company's revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.17 earnings per share. Research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.
Becton, Dickinson and Company declared that its Board of Directors has authorized a share buyback plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company's management believes its stock is undervalued.
Becton, Dickinson and Company Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.47%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is 69.10%.
Insider Activity at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, Director Jeffrey William Henderson acquired 1,500 shares of the company's stock in a transaction on Monday, February 10th. The shares were bought at an average cost of $233.62 per share, with a total value of $350,430.00. Following the completion of the acquisition, the director now owns 8,015 shares in the company, valued at approximately $1,872,464.30. This trade represents a 23.02 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bertram L. Scott sold 700 shares of the business's stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $227.99, for a total value of $159,593.00. Following the completion of the sale, the director now owns 36,033 shares of the company's stock, valued at $8,215,163.67. This trade represents a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,578 shares of company stock worth $795,986 in the last three months. Company insiders own 0.36% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have commented on BDX. Bank of America cut Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price target for the company. in a research note on Thursday. William Blair cut shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Thursday. Barclays cut their price target on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating on the stock in a research note on Monday, April 7th. The Goldman Sachs Group downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price objective for the company. in a research note on Friday. Finally, Stifel Nicolaus reduced their target price on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research note on Friday. Seven analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company has a consensus rating of "Hold" and a consensus target price of $235.88.
View Our Latest Stock Analysis on Becton, Dickinson and Company
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Read More
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
